226 related articles for article (PubMed ID: 37168932)
1. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
Alanaeme CJ; Bittner V; Brown TM; Colantonio LD; Dhalwani N; Jones J; Kalich B; Exter J; Jackson EA; Levitan EB; Poudel B; Wang Z; Woodward M; Muntner P; Rosenson RS
Am Heart J Plus; 2022 Sep; 21():. PubMed ID: 37168932
[TBL] [Abstract][Full Text] [Related]
2. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.
Sakhuja S; Bittner VA; Brown TM; Farkouh ME; Levitan EB; Safford MM; Woodward M; Chen L; Sun R; Dhalwani N; Jones J; Kalich B; Exter J; Muntner P; Rosenson RS; Colantonio LD
Cardiovasc Drugs Ther; 2023 Apr; ():. PubMed ID: 37052867
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
[TBL] [Abstract][Full Text] [Related]
5. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP;
Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451
[TBL] [Abstract][Full Text] [Related]
6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
7. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus.
Saag JL; Gross D; Stirt D; Espina Rey A; Gros B
Cureus; 2023 Jun; 15(6):e40905. PubMed ID: 37492827
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
9. The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
McKinley EC; Bittner VA; Brown TM; Chen L; Exter J; Farkouh ME; Huang L; Jackson EA; Levitan EB; Orroth KK; Reading SR; Rosenson RS; Safford MM; Woodward M; Muntner P; Colantonio LD
Cardiovasc Drugs Ther; 2023 Feb; 37(1):107-116. PubMed ID: 34599698
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Poudel B; Rosenson RS; Bittner V; Gutiérrez OM; Anderson AH; Woodward M; Deo R; Carson AP; Mues KE; Dluzniewski PJ; Jaar BG; Lora CM; Taliercio J; Muntner P; Colantonio LD;
Kidney Med; 2021; 3(5):722-731.e1. PubMed ID: 34693254
[TBL] [Abstract][Full Text] [Related]
11. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
12. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
McEvoy JW; Daya N; Rahman F; Hoogeveen RC; Blumenthal RS; Shah AM; Ballantyne CM; Coresh J; Selvin E
JAMA; 2020 Jan; 323(4):329-338. PubMed ID: 31990314
[TBL] [Abstract][Full Text] [Related]
13. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
[TBL] [Abstract][Full Text] [Related]
14. Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Colvin CL; Poudel B; Bress AP; Derington CG; King JB; Wen Y; Chen L; Bittner V; Brown TM; Monda KL; Mues KE; Rosenson RS; Jackson EA; Muntner P; Colantonio LD
J Clin Lipidol; 2021; 15(5):665-673. PubMed ID: 34452823
[TBL] [Abstract][Full Text] [Related]
15. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.
Lee JC; Zdrojewski T; Pencina MJ; Wyszomirski A; Lachacz M; Opolski G; Bandosz P; Rutkowski M; Gaciong Z; Wyrzykowski B; Navar AM
JAMA Cardiol; 2016 Sep; 1(6):700-7. PubMed ID: 27434662
[TBL] [Abstract][Full Text] [Related]
16. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
17. Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States.
Klimchak AC; Patel MY; Iorga ŞR; Kulkarni N; Wong ND
Am J Prev Cardiol; 2020 Mar; 1():100010. PubMed ID: 34327452
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
Pagidipati NJ; Navar AM; Mulder H; Sniderman AD; Peterson ED; Pencina MJ
JAMA; 2017 Apr; 317(15):1563-1567. PubMed ID: 28418481
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
[TBL] [Abstract][Full Text] [Related]
20. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
